Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.

EP: 1.Case Presentation: A 67-Year-Old-Man with Metastatic Prostate Cancer

EP: 2.Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP: 3.Factors for Consideration When Selecting Treatments for Patients with mCRPC

EP: 4.The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer

Now Viewing

EP: 5.Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

Related Videos

Related Content

Advertisement

Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor

More than 80% of patients in both groups had a full recovery of testosterone.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

April 25th 2025

FDA clears AI-powered application for measuring prostate volume

Benjamin P. Saylor

Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.

April 23rd 2025

Study shows IsoPSA’s predictive ability for clinically significant prostate cancer

Hannah Clarke

"In this large study of over 1500 men with an elevated PSA, we found that a low IsoPSA is incredibly reassuring,” says Christopher J. Weight, MD.

Related Content

Advertisement

Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor

More than 80% of patients in both groups had a full recovery of testosterone.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

April 25th 2025

FDA clears AI-powered application for measuring prostate volume

Benjamin P. Saylor

Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.

April 23rd 2025

Study shows IsoPSA’s predictive ability for clinically significant prostate cancer

Hannah Clarke

"In this large study of over 1500 men with an elevated PSA, we found that a low IsoPSA is incredibly reassuring,” says Christopher J. Weight, MD.